Quick Answer
Annovis Bio, Inc. reported Common Stock Shares Outstanding of 27.20 million shares for the year ending 2025.
- Annovis Bio, Inc. showed an increase of +92.3% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Annovis Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2019 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: 6.85 million shares | Q2 2020: 6.87 million shares | Q3 2020: 6.87 million shares | Q1 2021: 6.95 million shares | Q2 2021: 8.09 million shares | Q3 2021: 8.10 million shares | Q4 2021: 8.10 million shares | Q1 2022: 8.16 million shares | Q2 2022: 8.16 million shares | Q3 2022: 8.16 million shares | Q1 2023: 8.22 million shares | Q2 2023: 9.01 million shares | Q3 2023: 9.01 million shares | Q1 2024: 11.01 million shares | Q2 2024: 11.72 million shares | Q3 2024: 13.28 million shares | Q1 2025: 19.49 million shares | Q2 2025: 19.49 million shares | Q3 2025: 20.19 million shares.
- Over the full 10 years of available data (2019 to 2025), Annovis Bio, Inc.'s Common Stock Shares Outstanding has grown by 9,524.1%.
- Historical annual values: Fiscal year 2025: 27.20 million shares | Fiscal year 2024: 14.14 million shares | Fiscal year 2023: 10.52 million shares | Fiscal year 2022: 8.16 million shares | Fiscal year 2022: 8.16 million shares | Fiscal year 2022: 8.16 million shares | Fiscal year 2022: 8.16 million shares | Fiscal year 2021: 8.10 million shares | Fiscal year 2020: 6.89 million shares | Fiscal year 2019: 282,614 shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: